|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Cardiology (Dr. Vigna, Stanislao, De Rito, Russo, and Santoro), "Casa Sollievo della Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, Roma, Italy; and the Institute of Cardiology (Drs. Natali and Loperfido), Università Cattolica del Sacro Cuore, Roma, Italy.
Correspondence to: Francesco Loperfido, MD, Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Complesso Integrato Columbus, Via G. Moscati, 31/33, 00168 Roma, Italy; e-mail: loperfido{at}tiscalinet.it
| Abstract |
|---|
|
|
|---|
Design: Comparison of DSE and dipyridamole sestamibi myocardial perfusion scintigraphy (sestamibi).
Setting: Tertiary-care cardiac referral center.
Patients: Fifty-four consecutive patients (26 men; mean [ ± SD] age, 59 ± 7 years) with complete LBBB (14 patients with left ventricular [LV] dilatation) and intermediate probability of CAD.
Methods: Simultaneous single photon emission CT
scan (20 mCi technetium Tc 99m stress/rest sestamibi) and
echocardiography (second harmonic imaging) during a two-step (0.56 to
0.84 mg/kg) dipyridamole infusion protocol. Two sestamibi readings were
performed. The first reading considered only those studies with
reversible defects (sestamibi-1) to be positive. The second reading
considered those studies with any defect (sestamibi-2) to be
positive. CAD was defined as a
50% reduction in diameter in
at least one major vessel seen on coronary angiography.
Results: CAD was present in 17 patients (31.5%). The global predictive accuracy for CAD was significantly higher for DSE (87.0%) and sestamibi-1 (79.6%) than for sestamibi-2 (57.4%) [p < 0.01 vs DSE; p < 0.05 vs sestamibi-1]. No significant differences in sensitivity were present, but specificity was significantly higher for DSE (94.6%) and sestamibi-1 (81.1%) than for sestamibi-2 (43.2%; p < 0.01 vs both the other two tests). Of 14 patients with LV dilatation, 26.8% were falsely positive for CAD (in some cases for posterior defects) as determined by sestamibi-1 and 64.3% were falsely positive for CAD by sestamibi-2 vs none by DSE.
Conclusions: DSE is at least as accurate as dipyridamole sestamibi scintigraphy for predicting CAD in patients with complete LBBB and tends to be more specific in those patients with underlying LV dilatation.
Key Words: left bundle-branch block myocardial perfusion scintigraphy stress echocardiography
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
50% reduction in diameter of at least one major
vessel.
DSE
A second harmonic imaging procedure was performed in all
patients (Sonos 5500 System; Hewlett-Packard; Andover, MA). Studies
were digitized in a quad-screen format and were analyzed by two
investigators who were blinded to each others data. The left
ventricular (LV) end-diastolic internal dimension was measured by
M-mode. The LV ejection fraction was calculated as the mean from
4-chamber and 2-chamber apical views (area-length method). Patients
with an LV end-diastolic internal dimension of > 60 mm were
considered to have LV dilatation. The LV was divided into 16 segments,
according to the guidelines of the American Society of
Echocardiography.8
Segments tributary of the right
and circumflex coronary artery constituted the posterior region. The
other segments, including an isolated apical abnormality, constituted
the anterior region. Both endocardial shortening and wall thickening
were analyzed in all segments, including the ventricular septum. Normal
septal motion was considered to be present when, apart from early
paradoxical systolic movement, (relatively) normal posterior shortening
and thickening were evident in systole.9
A wall motion
score index was calculated using a 4-point scale (1, normal; 4,
dyskinetic). A study was considered to be positive in the presence of a
new or worsening wall motion abnormality in one or more segment of one
region. The condition of akinesia becoming dyskinesia was not
considered.10
The intraobserver and interobserver
variabilities for segmental readings in our laboratory were 2.6% and
3.6%, respectively.
Sestamibi
Stress/rest single photon emission CT was performed (20 mCi Tc
99m sestamibi). Short-axis, horizontal long-axis, and vertical
long-axis slices were acquired and were interpreted by two
investigators who were blinded to each others data. The LV was
divided into 16 segments which were attributed to the anterior or
posterior region, as for echocardiography. Only vertical and horizontal
long-axis slices were used to define the apex. Sestamibi uptake was
visually evaluated with the assistance of a circumferential profile
analysis. Segmental uptake was classified using a 4- point scale
(normal, 0; equivocal or minimally reduced, 1; moderately reduced, 2;
severely reduced, 3). Studies were considered to be positive only in
the presence of reversible defects (sestamibi-1) or, alternatively, in
the presence of any grade-2 to grade-3 defect in at least one segment
of one region (sestamibi-2).3
The intraobserver and
interobserver variabilities for sestamibi segmental readings in our
laboratory were 2.1% and 2.6%, respectively.
Statistical Analysis
When appropriate, paired and unpaired t tests
and
2 tests were used. The predictive accuracy
for predicting CAD of DSE, sestamibi-1, and sestamibi-2 was compared by
the Cochran Q test. The same test also was applied to
separately compared true-positive results (sensitivity) and
true-negative results (specificity) for each diagnostic test. In case
of global statistical significance, pairwise multiple comparisons were
carried out by McNemar
2 test with the
appropriate Bonferroni correction. Calculating the percentage of
concordant diagnosis,
values and the corresponding 95% confidence
intervals (CIs) constituted the analysis of agreement between the three
tests.
| Results |
|---|
|
|
|---|
Dipyridamole Test Effects
Three patients (5.6%) received only the first dose of
dipyridamole because of new or worsening wall motion abnormalities.
Four patients (7.4%) complained of chest pain during the second dose
of dipyridamole. From baseline to the dipyridamole peak dose, heart
rate increased from 76 ± 11 to 93 ± 13 beats/min (p < 0.01),
systolic BP increased from 126 ± 16 to 127 ± 13 mm Hg (NS),
diastolic BP increased from 81 ± 6 to 80 ± 5 mm Hg (NS), the
rate-systolic BP product increased from 9,589 ± 1,580 to
11,736 ± 1,740 (p < 0.01), and the echocardiographic wall motion
score index increased from 1.4 ± 0.3 to 1.5 ± 0.4 (p < 0.001).
Diagnostic Performance of DSE, Sestamibi-1, and Sestamibi-2
The diagnostic performances of DSE, sestamibi-1, and sestamibi-2
in study group patients is shown in Table 1
and Figure 1
(separate data for anterior and posterior regions).
|
|
DSE tended to be more accurate than both sestamibi-1 and sestamibi-2 in the 14 patients with underlying LV dilatation (Table 2 ). In fact, 26.8% and 64.3% of patients, respectively, had falsely positive responses to sestamibi-1 and sestamibi-2 and no falsely positive responses to DSE (Fig 2 ). Remarkably, there were three reversible falsely positive posterior defects.
|
|
, 0.49; 95% CI, 0.25 to 0.72). Of 12 patients (22%)
with discordant DSE and sestamibi-1 responses, 9 had positive responses
on scintigraphy (7 false-positive responses). We found 30 patients
(55%) with concordant DSE and sestamibi-2 responses (
, 0.23; 95%
CI, 0.06 to 0.42). Of 24 patients (45%) with discordant DSE and
sestamibi-2 responses, 23 had positive responses on scintigraphy (20
false-positive responses). | Discussion |
|---|
|
|
|---|
DSE was very specific for CAD and, although it is less sensitive than sestamibi scintigraphy for one-vessel disease and in our patients with complete LBBB, it demonstrated an accuracy not inferior to that found in patients without LBBB.17 This good diagnostic performance of DSE was not anticipated. In fact, the evaluation of stress-induced contractile changes in patients with LBBB traditionally has been difficult to discern even for the experienced observer due to the presence of various degrees of anteroseptal asynergy at rest, which in some cases mimics the effects of an extensive anteroseptal infarction.18 However, regional wall motion analysis by echocardiography has been substantially facilitated by modern technology, such as second harmonic imaging.19 In fact, the endocardial border can be optimally imaged in most cases even at the level of the distal portion of the anterior and septal wall, as well as of the entire apex. Further imaging improvement can be achieved in the near field through the fine regulation of gain and focus settings. Modern computerized tools, such as color kinesis, may improve this approach. Moreover, septal motion can be more confidently evaluated by combining M-mode and two-dimensional echocardiographic analysis, as demonstrated by the recent data from the study by Geleijnse et al.9 Thus, giving particular attention also to the contractile behavior of the apex, a biphasic response suggesting inducible ischemia in the anterior region can be diagnosed even in patients showing severe LBBB-linked asynergy at baseline.
A new finding in our study with possible practical implications was that two thirds of patients with LBBB and underlying LV dilatation who were examined by sestamibi-2 and one third of patients with LBBB and underlying LV dilatation who were examined by sestamibi-1 had false-positive responses for CAD, compared with no false-positive responses when patients were examined by DSE. Remarkably, in these patients we observed some very misleading falsely positive posterior defects, which were similar to those noticed in patients with LV hypertrophy and/or dilatation20 21 22 and had been attributed to microcirculatory dysfunction or to partial volume effect. However, the cause of these defects in the presence of complete LBBB and LV dilatation remains unclear.
Some important limitations of our study should be acknowledged. First of all, the population examined was relatively small, particularly regarding patients with underlying LV dilatation. Consequently, our dismissal of scintigraphy in this subset of patients should be confirmed with a larger group of patients. Furthermore, we did not use new scintigraphic techniques that allow the combined analysis of myocardial perfusion and wall motion,23 which might have provided better results than those found in this study. Finally, different results might have been observed in an LBBB population with different pretest probabilities for CAD.
In conclusion, our data show that echocardiography during dipyridamole infusion is at least as accurate as dipyridamole myocardial perfusion scintigraphy for predicting CAD in patients with LBBB and suggest that DSE may be particularly appropriate in patients with underlying LV dilatation.
| Acknowledgements |
|---|
| Footnotes |
|---|
Received for publication July 21, 2000. Accepted for publication May 22, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C Y Loong and C Anagnostopoulos Diagnosis of coronary artery disease by radionuclide myocardial perfusion imaging Heart, August 1, 2004; 90(suppl_5): v2 - v9. [Full Text] [PDF] |
||||
![]() |
E. Picano Specificity of non invasive pacemaker stress echocardiography in the diagnosis of coronary artery disease: Reply J. Am. Coll. Cardiol., March 19, 2003; 41(6): 1069 - 1069. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |